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Abstract
HIV-1 R5 viruses vary widely in their capacity to infect primary macrophages. R5 macrophage-tropism is associated 
with an increased envelope:CD4 affinity that partly results from an increased exposure of CD4 contact residues on 
gp120 and allows the use of low levels of CD4 for infection. The selective pressures in vivo that modulate R5 
macrophage-tropism are not understood. It is possible that different R5 variants adapt for replication in either T-cells 
(high CD4) or in macrophages (low CD4). However, other selective pressures in vivo (e.g. neutralizing antibodies) may 
also impact R5 tropism. Here, we measured macrophage infectivity conferred by gp120 sequences amplified 
sequentially from subjects in London followed from the acute stage of infection. We report wide variation in the 
capacity of these envelopes to confer macrophage infection in the complete absence of both autologous and 
heterologous neutralizing antibodies. Our data show that the variation in macrophage tropism observed at early times 
cannot have been influenced by neutralizing antibodies.
Findings
HIV-1 R5 viruses that use CCR5 (R5) as a coreceptor are
preferentially transmitted. Although such viruses are
often termed macrophage-tropic or M-tropic [1], we and
others have described a wide variation in their capacity to
infect primary macrophages [2-7]. In particular, we
showed that R5 envelopes amplified from brain tissue of
subjects with neurological complications were frequently
highly macrophage-tropic (mac-tropic), while many of
those from immune tissue, blood, and semen infected
macrophages inefficiently [3]. The capacity of R5 enve-
lopes to confer infection of macrophages correlated with
their sensitivity to inhibitors that blocked envelope: CD4
interactions, but not with those targeting envelope:CCR5
interactions or gp41 conformational changes [8]. These
observations indicated that R5 mac-tropism was modu-
lated by changes in the affinity of envelope for CD4. R5
mac-tropism also correlated with the capacity of enve-
lopes to infect cells via low levels of CD4 [2,3,9,10] con-
sistent with infection of macrophages that express
substantially lower amounts of CD4 compared to T-cells
[11-13]. In agreement with these observations, we and
others have identified gp120 determinants within or
proximal to the CD4 binding site (CD4bs) that modulate
R5 mac-tropism [11-16].
The selective pressures in vivo that drive changes in the
mac-tropism of R5 envelopes are poorly understood. It is
possible that the different R5 mac-tropic phenotypes
result from adaptation for replication in T-cells (high
CD4) or in macrophages (low CD4). However, R5 mac-
tropism forms a spectrum rather than two separate phe-
notypes. Thus, other selective pressures in vivo need to
be considered including neutralizing antibodies (nabs).
We previously reported a trend where mac-tropic R5
envelopes were more sensitive to the CD4bs monoclonal
antibody, b12, while Dunfee et al. reported a significant
correlation for envelopes derived from brain and lymph
node tissue [17]. Thus, the presence of CD4bs antibodies
in vivo may select for variants where the CD4bs is pro-
tected from neutralization. This possibility was sup-
ported by our identification of determinants on the flanks
of the CD4 binding loop that modulate mac-tropism and
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affect b12 sensitivity [14,18]. Such determinants presum-
ably affect the exposure of proximal CD4 contact residues
on the CD4 binding loop, which is likely the first contact
for CD4 [19]. The protection of these CD4 contact resi-
dues from antibodies may compromise the affinity of
envelope for CD4 and in turn restrict tropism to cells
expressing higher levels of CD4 (e.g. T-cells). In support
of this hypothesis, Ryzhova et al. reported that the pres-
ence of nabs in the CSF correlated with the absence of M-
tropic SIVs in rhesus macaques [20]. The predominance
of highly mac-tropic envelopes in brain tissue could also
reflect adaptation in an immuno-privileged site where
antibodies are excluded by the blood brain barrier and
usually reach only low concentrations [21,22]. However,
brain macrophages and microglia are the predominant
targets for HIV-1 in the brain, and the presence of highly
mac-tropic variants there may simply reflect an adapta-
tion for infection of these low CD4 cell types.
Here, we have investigated mac-tropism of gp120
sequences amplified sequentially from subjects in Lon-
don followed from the acute stage of infection. We report
wide variation in the capacity of 'early' envelopes to con-
fer macrophage infection in the complete absence of
nabs.
We investigated 36 gp120s amplified from three sub-
jects (Table 1) sampled from 12 days to over 7 years after
the onset of acute phase symptoms. At early times,
gp120s were amplified by nested PCR from proviral DNA
in PBMCs, as this was a sensitive approach. At later
times, gp120s were amplified from viral RNA in plasma
to avoid accumulated archival proviruses and when PCR
sensitivity was not an issue. The gp120 sequences were
cloned into pHXB2 MCSΔenv via unique Bst EII and Mlu
I restriction sites [23]. Replication competent virus was
harvested from 293T cells 48 hours after transfection.
Infectivity was then estimated by titration on HeLa TZM-
bl cells and at least two batches of primary macrophages.
In addition, sequential serum samples from the same sub-
jects were tested for neutralization of env+ pseudovirions
carrying autologous or heterologous envelopes.
All 36 gp120 sequences investigated conferred efficient
infection of HeLa TZM-bl cells that express high levels of
CD4 [24] (Figure 1). All envelopes conferred an R5 phe-
notype except for those from MM8 day 957 which were
R5X4 (not shown). We observed extensive variation in
macrophage infectivity among the envelopes. For MM1,
two envelopes from 28 days after the onset of acute phase
symptoms conferred highly divergent levels of mac-
rophage infectivity (Figure 1). Envelopes amplified from
84 and 833 days conferred only very inefficient infection
of macrophages, while more substantial levels mac-
rophage infection were observed with envelopes ampli-
fied after several years (day 2702) of infection. Similar
variation in macrophage infectivity was observed with
envelopes amplified from subjects MM4 and MM8. Of
note, envelopes that varied dramatically in their capaci-
ties to infect macrophages were amplified from the same
time point at days 17 and 493 for MM4, days 12 and 608
for MM8 and (as already stated) day 28 for MM1. In con-
trast envelopes from later time points (day 2702 for
Table 1: Subject Details: Viral Load, CD4 counts and envelope PCR
MM1 Daya 21 28 48 84 195 494 833 1231 1879 2702
VLb 81,000 34,400 14,900 5,400 60,000 63,400 169,300 32,100 111,600 22,200
CD4c 880 ndd nd 1000 nd 660 830 740 690 530
env PCRe DNA DNA RNA RNA
MM4 Day 17 52 108 206 297 493 574 844 1058 1191
VL 160,000 9,900 42,300 30,200 24,000 19,900 34,500 137,200 nd 233,400
CD4 nd 990 590 750 610 690 610 650 nd 490
env PCR DNA RNA RNA
MM8 Day 12 32 49 81 200 333 608 810 957
VL 5,927,000 nd 454,100 41,900 59,000 44,500 41,800 105,200 154,800
CD4 290 nd 610 350 410 420 260 240 90
env PCR DNA DNA RNA RNA
a. Days counted from onset of symptoms characteristic of primary HIV infection (fever, myalgias, lethargy, a sore throat, headaches, anorexia, 
diarrhea).
b. VL, plasma viral load (RNA copies/ml) determined using Chiron 3.0 (Emeryville, Cal. USA).
c. CD4, CD4 cell numbers (cells/μl).
d. nd, not determined.
e. DNA or RNA source of envelope PCR.
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Figure 1 Macrophage infectivity conferred by HIV-1 gp120 sequences amplified from the acute phase of replication and at various times 
post-seroconversion. Replication competent HIV-1 clones carrying gp120 sequences amplified sequentially from subjects MM1, MM4 and MM8 in 
London were tested for infection of HeLa TZM-bl cells and primary macrophages.
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MM1, day 844 for MM4, and day 957 for MM8) con-
ferred more uniform levels of macrophage infectivity,
with MM8 envelopes imparting higher levels of mac-
rophage infection compared to those from MM4.
Envelope residues that modulate macrophage tropism
have been reported to reside within or proximal to CD4
contact residues [14,15]. We examined closely related
pairs of gp120 sequences that differed in macrophage
infectivity for amino acid differences within or close to
the CD4bs that might be responsible for the shift in tro-
pism. Such differences were readily apparent even though
each pair of gp120 sequences had relatively few amino
acid changes (Table 2). Differences in CD4 contact resi-
dues were identified for MM4 and MM8 envelopes and in
the V3 loop for MM1 (Table 2). Confirmation of whether
these residues are responsible for the shifts in mac-tro-
pism observed will, however, require mutagenesis stud-
ies.
Heat inactivated plasma taken during and following the
acute stage of infection were tested for the presence of
autologous and heterologous nabs. We first investigated
whether we could detect nabs that neutralized heterolo-
gous viruses (Figure 2, left panels). We tested for neutral-
ization of HIV-1 IIIB and YU2 molecular clones. IIIB is a
T-cell line adapted HIV-1 variant, which is highly sensi-
tive to heterologous neutralization, while YU2 is a more
resistant primary strain. No neutralization of YU2 was
observed for any of the serum samples tested. Addition-
ally, no neutralization of IIIB was detected for IIIB in
serum samples up to day 1231 for MM1 and day 574 for
MM4, while no neutralization of IIIB was detected at all
for MM8 (last time point assayed was day 957). These
observations indicate that variation in macrophage tro-
pism occurred in the complete absence of nabs that target
conserved epitopes including the CD4bs. To test for
autologous nabs, we used the viral clones carrying gp120
sequences from early time points for MM1 (1.2.1, 1.2.3
from day 28 and 1.5.58 from day 84), MM4 (4.1.33 from
day 17 and 4.4.48 from day 52) and MM8 (8.2.50, 8.2.51
from day 12 and 8.4.51 from day 32). We failed to detect
autologous nabs against these viral clones until day 494
for MM1, day 206 for MM4 and day 81 for MM8 (Figure
2, right panels). Viral clones that varied in macrophage-
tropism were therefore identified well before the detec-
tion of nabs in each of the three subjects.
HIV-1 R5 envelopes that vary dramatically in their
capacities to infect macrophages were detected early after
infection and long before nabs develop. For the three sub-
jects investigated here, envelopes that varied in mac-
rophage infection were detected at 28, 17 and 12 days
respectively after the onset of acute stage symptoms.
However, we were unable to detect autologous or heterol-
ogous nabs until many weeks or months later. The identi-
fication of macrophage-tropic variants early in disease
seems at variance with the study by Salazar-Gonzalez et
al. [25] who reported weak macrophage-tropism among
'so called' founder strains. However, such strains are
believed to represent transmitted viruses rather than
those from acute phase plasma studied here. Our study
could be consistent with Isaacman-Beck's who showed a
range of macrophage infectivity among the clade C enve-
lopes, amplified from near acute phase plasma, although
these authors did not investigate the envelopes' temporal
relationship with nabs.
Our study shows that the selective pressures that confer
variation in R5 mac-tropism in the early stages of infec-
tion do not involve nabs and thus remain unclear. How-
ever, there remains the possibility that ADCC and or
complement mediated antibody functions play a role. In
addition, when nabs do arise, they are likely to act as a
Table 2: Envelope residues potentially involved in modulating macrophage-tropism
Subject Days post onset 
of symptoms
Env clone Mac infn Potential amino acid tropism determinants
No. amino acid changes in gp120 Env region Amino acid changes
MM1 28 1.2.1 - 5 V3 loop NNSRKGIHIGPGRAFY
1.2.3 + --T-----------L-
MM4 17 4.1.33 - 5 β24-α5 GGD1
4.1.34 + --N
493 4.10.1 - 3 β24-α5 GGDMG1
4.10.3 + ----R
MM8 608 8.8.1 - 11 β20-β21 NRWQEA1
8.8.3 + -----V
1. Amino acids that are CD4 contact residues are underlined on upper sequences [26].
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Figure 2 Detection of neutralizing antibodies present in the plasma of subjects who yielded gp120 sequences studied here. Serially collect-
ed plasma samples (heat inactiviated) were tested for neutralization of YU2 and HTLV-IIIB, a sensitive T-cell line adapted HIV-1 strain (left panels). The 
same plasma samples were tested for neutralization of viral clones carrying autologous gp120s from the early stages of infection (right panels). Missing 
arrows or bars means not tested.
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selective pressure that impacts on tropism. This could be
particularly true for heterologous nabs that target the
CD4bs thus favouring non-mac-tropic variants that pro-
tect this site.
In summary, we show that variation in macrophage tro-
pism observed at early times in HIV-1 infection has not
been influenced by neutralizing antibodies.
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